Markets:

Overview

News

Currencies

International

Treasuries

Insmed Incorporated - Common Stock (NQ:INSM)

163.59 +1.16 (+0.72%)

Streaming Delayed Price Updated: 2:46 PM EDT, Apr 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Insmed Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

May 13, 2025

Via Benzinga

Analyst Expectations For Insmed's Future ↗

May 12, 2025

Via Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today ↗

May 09, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

May 05, 2025

Via Benzinga

Is Insmed Gaining or Losing Market Support? ↗

May 01, 2025

Via Benzinga

Here's How Much You Would Have Made Owning Insmed Stock In The Last 5 Years ↗

March 05, 2025

Via Benzinga

Earnings Scheduled For February 20, 2025 ↗

February 20, 2025

Via Benzinga

Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today ↗

February 14, 2025

Via Benzinga

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today ↗

April 25, 2025

Via Benzinga

In The Holiday Shortened Easter Week, These Large-Cap Stock Were Top Performers (Apr 14-Apr 18): Are These In Your Portfolio? ↗

April 20, 2025

Top performers last week: ServiceTitan, Summit Therapeutics, YPF, Eli Lilly, MicroStrategy, America Movil, Ericsson, Insmed, Diamondback, Neurocrine Biosciences.

Via Benzinga

Here's How Much You Would Have Made Owning Insmed Stock In The Last 5 Years ↗

April 15, 2025

Via Benzinga

Friday's after hours session: top gainers and losers ↗

April 11, 2025

As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Peering Into Insmed's Recent Short Interest ↗

February 14, 2025

Via Benzinga

Insmed Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) ↗

February 11, 2025

Via Benzinga

Here's How Much You Would Have Made Owning Insmed Stock In The Last 5 Years ↗

February 05, 2025

Via Benzinga

A technical analysis of INSMED INC (NASDAQ:INSM). ↗

March 28, 2025

INSMED INC (NASDAQ:INSM) Reveals Intriguing Technical Aspects. Indications Suggest NASDAQ:INSM Could Be on the Verge of a Breakout. Here's What You Need to Know.

Via Chartmill

$1000 Invested In Insmed 10 Years Ago Would Be Worth This Much Today ↗

March 25, 2025

Via Benzinga

Expert Outlook: Insmed Through The Eyes Of 13 Analysts ↗

March 19, 2025

Via Benzinga

One Vanguard Index Fund to Buy That May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst ↗

March 15, 2025

Via The Motley Fool

Topics Stocks

Are Small-Cap Stocks A Buy After Russell 2000 Correction? ↗

March 06, 2025

Investors are questioning the value of small-cap stocks, as reflected by Russell 2000's 15% drop. Some top stocks saw even bigger declines.

Via Benzinga

How Is The Market Feeling About Insmed? ↗

January 13, 2025

Via Benzinga

Here's How Much You Would Have Made Owning Insmed Stock In The Last 10 Years ↗

January 02, 2025

Via Benzinga

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today ↗

December 16, 2024

Via Benzinga

First Trust's New Small-Cap ETF Aims To Combine Growth With Income ↗

February 28, 2025

First Trust launches actively managed FTKI ETF, using buy-write strategy for steady income and small-cap exposure. Expense ratio is 0.85%.

Via Benzinga

Topics ETFs

Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says ↗

February 25, 2025

RBC Capital initiates Insmed with an Outperform rating, citing brensocatib's launch potential and Arikayce's growth. FDA decision on brensocatib due August 2025.

Via Benzinga

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

February 25, 2025

Via Benzinga

Goldman Sachs Sees High Merger Odds For This Large-Cap Biopharma In Trump 2.0 Era: Retail Has Been Alert ↗

January 16, 2025

Insmed specializes in treatments for rare and serious diseases and is currently advancing its lead asset, brensocatib, a potential first-in-class therapy for bronchiectasis.

Via Stocktwits

Topics Government

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗

January 10, 2025

The Benzinga Stock Whisper Index looks at five stocks receiving increased attention from readers during the week and provides potential reason why.

Via Benzinga

1 Vanguard Index Fund to Buy to Beat the S&P 500 in 2025, According to a Wall Street Bank ↗

December 17, 2024

Via The Motley Fool

Topics Stocks

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.